
浏览全部资源
扫码关注微信
1.广西中医药大学,南宁 530001
2.广西中医药防治医学分子生物重点实验室,南宁 530001
3.广西中医药大学 附属瑞康医院,南宁 530001
黎敏航,在读硕士,从事中西医结合基础研究,E-mail:412276802@qq.com
罗伟生,博士,教授,从事中西医结合治疗脾胃肝病研究,E-mail:4011188@qq.com
收稿日期:2022-01-08,
网络出版日期:2022-05-25,
纸质出版日期:2022-11-20
移动端阅览
黎敏航,马晓聪,唐燕等.基于JAK2/STAT3信号通路探讨荔枝核总黄酮对HepG2增殖、迁移与侵袭的影响[J].中国实验方剂学杂志,2022,28(22):85-92.
LI Minhang,MA Xiaocong,TANG Yan,et al.Effect of Total Flavone of Litchi Semen on Proliferation, Migration, and Invasion of HepG2 Cells Based on JAK2/STAT3 Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(22):85-92.
黎敏航,马晓聪,唐燕等.基于JAK2/STAT3信号通路探讨荔枝核总黄酮对HepG2增殖、迁移与侵袭的影响[J].中国实验方剂学杂志,2022,28(22):85-92. DOI: 10.13422/j.cnki.syfjx.20221522.
LI Minhang,MA Xiaocong,TANG Yan,et al.Effect of Total Flavone of Litchi Semen on Proliferation, Migration, and Invasion of HepG2 Cells Based on JAK2/STAT3 Signaling Pathway[J].Chinese Journal of Experimental Traditional Medical Formulae,2022,28(22):85-92. DOI: 10.13422/j.cnki.syfjx.20221522.
目的
2
观察荔枝核总黄酮(TFL)对人肝癌细胞HepG2株增殖、凋亡、迁移与侵袭的影响。
方法
2
噻唑蓝(MTT)比色法检测不同浓度TFL及顺铂对HepG2细胞增殖的影响;TdT介导的dUTP缺口末端标记法(TUNEL)检测低、中、高质量浓度TFL(70、140、210 mg·L
-1
)及顺铂(60 mg·L
-1
)对HepG2细胞凋亡的影响,并选择TFL最优浓度进行后续实验。将细胞分为空白组、TFL组(140 mg·L
-1
)、TFL+XL019组(140 mg·L
-1
+0.5 μmol·L
-1
)、TFL+TPI-1组(140 mg·L
-1
+1 μmol·L
-1
),进行细胞划痕实验和小室侵袭实验以验证TFL对HepG2迁移和侵袭的影响;使用细胞免疫荧光技术检测TFL对HepG2细胞上皮间充质转化(EMT)标记物表达的影响;使用蛋白免疫印迹法(Westem blot)对TFL干预后细胞内的酪氨酸蛋白激酶2(JAK2)/信号传导及转录激活因子3(STAT3)信号通路上关键蛋白的表达情况进行检测。
结果
2
MTT比色法表明,与空白组比较,在24、48 h时,各质量浓度的TFL与顺铂均能显著抑制HepG2细胞增殖(
P
<
0.01),24、48 h时TFL对HepG2的半抑制浓度(IC
50
)分别为(136.7±2.40)、(106.8±1.11)mg·L
-1
,24、48 h时顺铂对HepG2的IC
50
分别为(58.48±2.04)、(5.15±0.56)mg·L
-1
。TUNEL法发现各质量浓度TFL均可以诱导HepG2细胞凋亡,由此结果确定TFL 140 mg·L
-1
为最佳质量浓度。细胞划痕实验表明,与空白组比较,TFL组、TFL+XL019组、TFL+TPI-1组均明显抑制HepG2细胞的迁移能力(
P
<
0.05,
P
<
0.01),与TFL组比较,TFL+XL019组的抑制作用明显增强(
P
<
0.05),TFL+TPI-1组的抑制作用显著减弱(
P
<
0.01)。小室侵袭实验表明,与空白组比较,TFL组、TFL+XL019组、TFL+TPI-1组干预都显著抑制了HepG2细胞的侵袭能力(
P
<
0.01),与TFL组比较,TFL+XL019组的抑制作用明显增强(
P
<
0.05),TFL+TPI-1组的抑制作用则显著减弱(
P
<
0.01)。荧光免疫结果表明,TFL的干预上调HepG2细胞上皮-钙黏蛋白(E-cadherin)的表达,同时下调波形蛋白(Vimentin)的表达,这种作用在TFL+XL019组中更强,在TFL+TPI-1组中则有所减弱;Western blot结果表明,与空白组比较,TFL组、TFL+XL019组、TFL+TPI-1组并未影响JAK2和STAT3蛋白的表达水平,但是明显降低磷酸化(p)-JAK2与p-STAT3表达水平(
P
<
0.05,
P
<
0.01),与TFL组比较,TFL+XL019组中的p-JAK2与p-STAT3的表达水平显著降低(
P
<
0.01),TFL+TPI-1组中p-JAK2与p-STAT3的表达水平显著升高(
P
<
0.01)。与空白组比较,TFL组显著增加了含sh2结构域的蛋白酪氨酸磷酸酶-1(SHP-1)表达水平(
P
<
0.01)。
结论
2
TFL可以抑制HepG2的增殖,促进其凋亡,还可以通过逆转HepG2细胞EMT的过程以减弱其迁移与侵袭的能力,这些作用可能与TFL激活SHP-1阻断JAK/STAT3信号通路相关。
Objective
2
To study the effect of total flavone of Litchi Semen (TFL) on proliferation, apoptosis, migration, and invasion of hepatoma cells HepG2.
Method
2
Methyl thiazolyl tetrazolium colorimetric (MTT) assay was used to detect the effect of different-dose TFL and cisplatin on the proliferation of HepG2 cells. TdT-mediated dUTP nick-end labeling (TUNEL) assay was used to detect the effects of low, medium, and high-dose (70, 140, 210 mg·L
-1
) of TFL and cisplatin (60 mg·L
-1
) on the apoptosis of HepG2 cells, thus selecting the optimal dose of TFL for the follow-up experiment. HepG2 cells were divided into a blank group, a TFL group (140 mg·L
-1
), a TFL+XL019 group (140 mg·L
-1
TFL+0.5 μmol·L
-1
XL019), and a TFL+TPI-1 group (140 mg·L
-1
TFL+1 μmol·L
-1
TPI-1). The effect of TFL on migration and invasion of HepG2 cells were examined by wound healing test and Transwell invasion assay, and the effect of TFL on the expression of epithelial-mesenchymal transition (EMT) marker in HepG2 cells were examined by cell immunofluorescence assay. Western blot was used to detect the expression of key proteins in Janus kinase 2(JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway after the intervention by TFL.
Result
2
MTT assay showed that the proliferation of HepG2 cells was significantly inhibited by TFL and cisplatin at 24 and 48 h as compared with blank group (
P
<
0.01), and the half maximal inhibitory concentration (IC
50
) of TFL on HepG2 cells was (136.7±2.40) mg·L
-1
at 24 h and (106.8±1.11) mg·L
-1
at 48 h. The IC
50
of cisplatin on HepG2 cells was (58.48±2.04) mg·L
-1
at 24 h and (5.15±0.56) mg·L
-1
at 48 h. The results of TUNEL assay showed that TFL induced apoptosis of HepG2 cells. The optimal dose of TFL was 140 mg·L
-1
. The results of wound healing test showed that compared with the blank group, the TFL group, TFL+XL019 group, and the TFL+TPI-1 group significantly inhibited the migration of HepG2 cells (
P
<
0.05,
P
<
0.01). As compared with the TFL group, the inhibitory effect of the TFL+XL019 Group was significantly increased (
P
<
0.05), while that of the TFL+TPI-1 group was significantly decreased (
P
<
0.01). The Transwell invasion assay showed that compared with the blank group, the TFL group, TFL+XL019 group, and the TFL+TPI-1 group significantly inhibited the invasion of HepG2 cells (
P
<
0.01). As compared with the TFL group, the inhibitory effect of the TFL+XL019 group was significantly increased (
P
<
0.05), while that of the TFL+TPI-1 group was significantly decreased (
P
<
0.01). The results of immunofluorescence showed the intervention of TFL up-regulated the expression of E-cadherin, and down-regulated the expression of Vimentin in HepG2 cells, which was stronger in the TFL+XL019 group and weaker in the TFL+TPI-1 group. The results of Western blot showed that compared with the blank group, the TFL group, TFL+XL019 group, and the TFL+TPI-1 group did not affect the expression of JAK2 or STAT3 protein, but significantly decreased the expression levels of phosphorylatied (p)-JAK2 and p-STAT3 (
P
<
0.05,
P
<
0.01). As compared with the TFL group, the expression levels of p-JAK2 and p-STAT3 in the TFL+XL019 group were significantly decreased (
P
<
0.01), while those in the TFL+TPI-1 group were significantly increased (
P
<
0.01). Compared with the blank group, the TFL group significantly increased the expression level of Src-homology domain 2 containing protein tyrosine phosphatase-1(SHP-1) with sh2 domain (
P
<
0.01).
Conclusion
2
TFL has the effects of inhibiting the proliferation, promoting apoptosis of HepG2 cells, and reversing the EMT process of HepG2 cells to reduce the migration and invasion, which are presumably related to the activation of SHP-1 by TFL to block JAK/STAT3 signaling pathway.
张楠 , 周志昆 , 张凌云 , 等 . 荔枝核与龙眼核水提取物的体外抗肿瘤活性的比较与评估 [J]. 湖南中医杂志 , 2012 , 28 ( 3 ): 133 - 135 .
肖柳英 , 张丹 , 冯昭明 , 等 . 荔枝核对小鼠抗肿瘤作用研究 [J]. 中药材 , 2004 , 27 ( 7 ): 517 - 518 .
陈剑梅 , 郭洁文 , 徐峰 . 荔枝核活性成分提取及药理作用的研究进展 [J]. 今日药学 , 2011 , 21 ( 11 ): 710 - 712,720 .
罗伟生 , 靳雅玲 , 欧士钰 , 等 . 荔枝核总黄酮对肝纤维化大鼠肝细胞Bcl-2/Bax表达的影响 [J]. 世界华人消化杂志 , 2012 , 20 ( 18 ): 1602 - 1608 .
黄红 , 康毅 , 黄旭平 , 等 . 荔枝核总黄酮对大鼠肝纤维化Smad3、Smad4及TIMP-1信号表达的影响 [J]. 世界华人消化杂志 , 2016 , 24 ( 2 ): 176 - 186 .
欧士钰 , 罗伟生 , 靳雅玲 , 等 . 荔枝核总黄酮对肝纤维化大鼠肝组织MMP-2表达的影响 [J]. 中国实验方剂学杂志 , 2012 , 18 ( 13 ): 209 - 213 .
LV Y , ZHAO X , ZHU L , et al . Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis [J]. Theranostics , 2018 , 8 ( 10 ): 2830 - 2845 .
冯宇 , 刘雪梅 , 罗伟生 , 等 . 大孔树脂纯化荔枝核总黄酮工艺研究 [J]. 中草药 , 2019 , 50 ( 9 ): 2087 - 2093 .
HU X , JIAO F , ZHANG L , et al . Dihydrotanshinone inhibits hepatocellular carcinoma by suppressing the JAK2/STAT3 pathway [J]. Front Pharmacol , 2021 , doi: 10.3389/fphar.2021.654986 http://dx.doi.org/10.3389/fphar.2021.654986 .
LEE H , JEONG A J , YE S K . Highlighted STAT3 as a potential drug target for cancer therapy [J]. BMB Rep , 2019 , 52 ( 7 ): 415 - 423 .
HUYNH J , CHAND A , GOUGH D , et al . Therapeutically exploiting STAT3 activity in cancer - using tissue repair as a road map [J]. Nat Rev Cancer , 2019 , 19 ( 2 ): 82 - 96 .
LIU K , REN T , HUANG Y , et al . Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma [J]. Cell Death Dis , 2017 , 8 ( 8 ): e3015 .
BAI L , ZHOU H , XU R , et al . A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo [J]. Cancer Cell , 2019 , 36 ( 5 ): 498 - 511 .
YEUNG K T , YANG J . Epithelial-mesenchymal transition in tumor metastasis [J]. Mol Oncol , 2017 , 11 ( 1 ): 28 - 39 .
FAN X , JIN S , LI Y , et al . Genetic and epigenetic regulation of E-cadherin signaling in human hepatocellular carcinoma [J]. Cancer Manag Res , 2019 , doi: 10.2147/CMAR.S225606 http://dx.doi.org/10.2147/CMAR.S225606 .
SATELLI A , LI S . Vimentin in cancer and its potential as a molecular target for cancer therapy [J]. Cell Mol Life Sci , 2011 , 68 ( 18 ): 3033 - 3046 .
ROKAVEC M , ÖNER MG , LI H , et al . IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis [J]. J Clin Invest , 2014 , 124 ( 4 ): 1853 - 67 .
LIN W H , CHANG Y W , HONG M X , et al . STAT3 phosphorylation at Ser727 and Tyr705 differentially regulates the EMT-MET switch and cancer metastasis [J]. Oncogene , 2021 , 40 ( 4 ): 791 - 805 .
SHEN M , XU Z , XU W , et al . Inhibition of ATM reverses EMT and decreases metastatic potential of cisplatin-resistant lung cancer cells through JAK/STAT3/PD-L1 pathway [J]. J Exp Clin Cancer Res , 2019 , 38 ( 1 ): 1 - 14 .
HUANG T T , SU J C , LIU C Y , et al . Alteration of SHP-1/p-STAT3 signaling: A potential target for anticancer therapy [J]. Int J Mol Sci , 2017 , 18 ( 6 ): 1234 .
TAI W T , SHIAU C W , CHEN P J , et al . Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma [J]. Hepatology , 2014 , 59 ( 1 ): 190 - 201 .
KUNDU S , FAN K , CAO M , et al . Novel SHP-1 inhibitors tyrosine phosphatase inhibitor-1 and analogs with preclinical anti-tumor activities as tolerated oral agents [J]. J Immunol , 2010 , 184 ( 11 ): 6529 - 6536 .
0
浏览量
23
下载量
1
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621